Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Autolus Therapeutics plc

< Previous 1 2 Next >
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Announces Changes to its Board of Directors
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces publication in Blood Cancer Journal
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces publication in Nature Communications
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Announces Pricing of Underwritten Offering
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces publication in ACS Chemical Biology
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Announces Changes to its Board of Directors
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.